Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria: * Refractory to or relapsed after at least 1 prior treatment regimen; * Eastern Cooperative Oncology Group (ECOG) score of 0 to 2; * At least 18 years of age. Exclusion Criteria: * Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks); * Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months; * Known hepatitis B virus, hepatitis C virus or HIV infection; * Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically inhibits the PI3K or mTOR pathway;